Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?

Alexander C Ford^{1

2}

Affiliations

¹ Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK alexford@nhs.net.
² Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Comment

Alexander C Ford. Gut. 2024.

. 2024 Feb 23;73(3):393-394.

doi: 10.1136/gutjnl-2024-331927.

Alexander C Ford^{1

2}

¹ Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK alexford@nhs.net.
² Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

No abstract available

Keywords: IRRITABLE BOWEL SYNDROME.

Conflict of interest statement

Competing interests: None declared.

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial.
Decraecker L, De Looze D, Hirsch DP, De Schepper H, Arts J, Caenepeel P, Bredenoord AJ, Kolkman J, Bellens K, Van Beek K, Pia F, Peetermans W, Vanuytsel T, Denadai-Souza A, Belmans A, Boeckxstaens G. Decraecker L, et al. Gut. 2024 Feb 23;73(3):459-469. doi: 10.1136/gutjnl-2023-331634. Gut. 2024. PMID: 38191268 Clinical Trial.